Nicotinamide riboside tartrate
Names
[ CAS No. ]:
2415657-86-0
[ Name ]:
Nicotinamide riboside tartrate
Biological Activity
[Description]:
Nicotinamide riboside tartrate, an orally active NAD+ precursor, increases NAD+ levels and activates SIRT1 and SIRT3. Nicotinamide riboside tartrate is a source of vitamin B3 (niacin) and enhances oxidative metabolism, protection against high fat diet-induced metabolic abnormalities[1]. Nicotinamide riboside tartrate reduces cognitive deterioration in a transgenic mouse model of Alzheimer’s disease[2].
[Related Catalog]:
[Target]
SIRT1
SIRT3
[In Vitro]
Nicotinamide riboside tartrate (0.5 nM; 24 hours) reduces the acetylation status of Ndufa9 and SOD2[1]. Nicotinamide riboside tartrate increases intracellular and mitochondrial NAD+ content in C2C12, Hepa1.6, and HEK293 cells in a concentration-dependent manner at concentrations ranging from 1-1000 μM[1]. Nicotinamide riboside tartrate boosts NAD to restore antiviral poly(ADP-ribose) polymerase (PARP) functions to support innate immunity for coronavirus (CoVs), a cause of COVID-19[3]. Western Blot Analysis[1] Cell Line: HEK293T cells Concentration: 0.5 nM Incubation Time: 24 hours Result: Reduced the acetylation status of Ndufa9 and SOD2.
[In Vivo]
Chronic Nicotinamide riboside tartrate (p.o.; 400 mg/kg/day; for 16 weeks) supplementation increases plasma and intracellular NAD+ content in a tissue-specific manner[1]. Animal Model: 10-week-old C57Bl/6J mice[1] Dosage: 400 mg/kg Administration: PO; daily; for 16 weeks Result: Increased plasma and intracellular NAD+ content in a tissue-specific manner.
[References]
Chemical & Physical Properties
[ Molecular Formula ]:
C15H20N2O11
[ Molecular Weight ]:
404.33